About Synaptojanin-2
Synaptojanin-2 (SYNJ2) is a protein
from Homo sapiens identified by UniProt accession
O15056, 1496 residues long.
MolForge cross-references it against 0 known binders and
135 disease associations.
Target properties
| Protein name | Synaptojanin-2 |
|---|
| UniProt accession | O15056 |
|---|
| Gene | SYNJ2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1496 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (2)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (135)
Diseases linked to this target (Open Targets).
- serum gamma-glutamyl transferase measurement · score 0.50
- alkaline phosphatase measurement · score 0.45
- platelet component distribution width · score 0.40
- intraocular pressure measurement · score 0.37
- neurodegenerative disease · score 0.34
- mean platelet volume · score 0.33
- cholelithiasis · score 0.30
- age-related hearing impairment · score 0.28
- glioblastoma multiforme · score 0.27
- breast adenocarcinoma · score 0.25
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O15056-F1 | alphafold | PREDICTED | 67.62 | — |
Amino-acid sequence (1496 residues)
MALSKGLRLL GRLGAEGDCS VLLEARGRDD CLLFEAGTVA TLAPEEKEVI KGQYGKLTDA YGCLGELRLK SGGTSLSFLV LVTGCTSVGR IPDAEIYKIT ATDFYPLQEE AKEEERLIAL KKILSSGVFY FSWPNDGSRF DLTVRTQKQG DDSSEWGNSF FWNQLLHVPL RQHQVSCCDW LLKIICGVVT IRTVYASHKQ AKACLVSRVS CERTGTRFHT RGVNDDGHVS NFVETEQMIY MDDGVSSFVQ IRGSVPLFWE QPGLQVGSHH LRLHRGLEAN APAFDRHMVL LKEQYGQQVV VNLLGSRGGE EVLNRAFKKL LWASCHAGDT PMINFDFHQF AKGGKLEKLE TLLRPQLKLH WEDFDVFTKG ENVSPRFQKG TLRMNCLDCL DRTNTVQSFI ALEVLHLQLK TLGLSSKPIV DRFVESFKAM WSLNGHSLSK VFTGSRALEG KAKVGKLKDG ARSMSRTIQS NFFDGVKQEA IKLLLVGDVY GEEVADKGGM LLDSTALLVT PRILKAMTER QSEFTNFKRI RIAMGTWNVN GGKQFRSNVL RTAELTDWLL DSPQLSGATD SQDDSSPADI FAVGFEEMVE LSAGNIVNAS TTNKKMWGEQ LQKAISRSHR YILLTSAQLV GVCLYIFVRP YHVPFIRDVA IDTVKTGMGG KAGNKGAVGI RFQFHSTSFC FICSHLTAGQ SQVKERNEDY KEITQKLCFP MGRNVFSHDY VFWCGDFNYR IDLTYEEVFY FVKRQDWKKL LEFDQLQLQK SSGKIFKDFH EGAINFGPTY KYDVGSAAYD TSDKCRTPAW TDRVLWWRKK HPFDKTAGEL NLLDSDLDVD TKVRHTWSPG ALQYYGRAEL QASDHRPVLA IVEVEVQEVD VGARERVFQE VSSFQGPLDA TVVVNLQSPT LEEKNEFPED LRTELMQTLG SYGTIVLVRI NQGQMLVTFA DSHSALSVLD VDGMKVKGRA VKIRPKTKDW LKGLREEIIR KRDSMAPVSP TANSCLLEEN FDFTSLDYES EGDILEDDED YLVDEFNQPG VSDSELGGDD LSDVPGPTAL APPSKSPALT KKKQHPTYKD DADLVELKRE LEAVGEFRHR SPSRSLSVPN RPRPPQPPQR PPPPTGLMVK KSASDASISS GTHGQYSILQ TARLLPGAPQ QPPKARTGIS KPYNVKQIKT TNAQEAEAAI RCLLEARGGA SEEALSAVAP RDLEASSEPE PTPGAAKPET PQAPPLLPRR PPPRVPAIKK PTLRRTGKPL SPEEQFEQQT VHFTIGPPET SVEAPPVVTA PRVPPVPKPR TFQPGKAAER PSHRKPASDE APPGAGASVP PPLEAPPLVP KVPPRRKKSA PAAFHLQVLQ SNSQLLQGLT YNSSDSPSGH PPAAGTVFPQ GDFLSTSSAT SPDSDGTKAM KPEAAPLLGD YQDPFWNLLH HPKLLNNTWL SKSSDPLDSG TRSPKRDPID PVSAGASAAK AELPPDHEHK TLGHWVTISD QEKRTALQVF DPLAKT
Explore Synaptojanin-2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets